Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors

NCT04126070 is registered in ClinicalTrials.gov with Xiao X. Wei, MD as lead sponsor.

NCT NCT04126070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04126070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors
Lead sponsor
Xiao X. Wei, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 11, 2020
Completion date
October 30, 2026
Enrollment
47 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hormone sensitive prostate cancer, metastasis prostate adenocarcinoma, prostate adenocarcinoma